Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) traded down 0.33% during midday trading on Thursday, reaching $5.96. 49,852 shares of the company’s stock traded hands. Titan Pharmaceuticals has a 12 month low of $2.57 and a 12 month high of $8.74. The stock has a market cap of $126.34 million and a P/E ratio of 20.14. The stock has a 50 day moving average of $5.75 and a 200-day moving average of $5.61.
Titan Pharmaceuticals (OTCMKTS:TTNP) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.02. The firm had revenue of $15 million for the quarter, compared to the consensus estimate of $15 million. On average, equities research analysts forecast that Titan Pharmaceuticals will post $0.25 EPS for the current fiscal year.
In related news, CEO Sunil Bhonsle acquired 10,000 shares of Titan Pharmaceuticals stock in a transaction on Monday, July 18th. The shares were acquired at an average cost of $4.96 per share, with a total value of $49,600.00. Following the transaction, the chief executive officer now owns 135,578 shares in the company, valued at $672,466.88. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Joseph A. Akers acquired 13,000 shares of Titan Pharmaceuticals stock in a transaction on Tuesday, July 19th. The shares were bought at an average cost of $4.85 per share, for a total transaction of $63,050.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $38,800. The disclosure for this purchase can be found here.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.
Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.